Table 1.
Summary of eligible studies included for meta-analysis.
| Study design | Number of patients | Cancer subtype | TNM staging | Sample | MACC1 detection | MACC1 cut-off | High MACC1 proportion | Outcome | HR obtainment | HR | 95% CI | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stein et al., 2012 [12, 13] | C | 294 | CRC | I–IV | Blood | qRT-PCR | Median value | 147/294 | OS | Estimated | 1.260 | 0.450–3.530 |
| Zhang et al., 2012 [14] | R | 90 | CRC | I–IV | Tissue | IHC | Score ≥ 5 | 78/90 | OS | Estimated | 2.240 | 1.220–4.100 |
| Kang et al., 2013 [15] | R | 317 | CRC | I–IV | Tissue | IHC | Positive cells > 20% | 176/317 | OS | Reported | 2.560 | 1.830–3.570 |
| Zhen et al., 2014 [16] | R | 323 | CRC | I–IV | Tissue | IHC | Staining score = 6 | 169/323 | OS | Reported | 1.410 | 0.737–2.699 |
| Ge et al., 2011 [17] | R | 128 | GC | I–IV | Tissue | IHC | Positive cells ≥ 20% | 61/128 | OS | Reported | 0.621 | 0.380–1.014 |
| Guo et al., 2013 [18] | R | 98 | GC | I–IV | Tissue | IHC | Score > 3 | 60/98 | OS | Estimated | 1.330 | 0.640–2.760 |
| Wang et al., 2013 [5] | R | 361 | GC | I–IV | Tissue | IHC | Score ≥ 3 | 280/361 | OS | Reported | 2.217 | 1.311–3.049 |
| Zhu et al., 2013 [9] | R | 85 | EC | I–III | Tissue | IHC | Score > 2 | 47/85 | OS | Reported | 2.250 | 1.180–4.280 |
| Yang et al., 2013 [19] | R | 120 | HCC | N/A | Tissue | qRT-PCR | Median value | 60/120 | OS | Reported | 1.842 | 1.201–2.514 |
| Qiu et al., 2011 [10] | R | 128 | HCC | I–III | Tissue | qRT-PCR | Threshold value | 57/128 | OS | Reported | 2.230 | 1.257–3.957 |
| Qu et al., 2012 [20] | R | 234 | HCC | N/A | Tissue | qRT-PCR | Value > 0.006 73 | 105/234 | OS | Reported | 1.508 | 1.079–1.835 |
| Ding et al., 2013 [21] | R | 66 | HCC | I–IV | Tissue | IHC | Positive cells > 50% | 33/66 | OS | Estimated | 2.190 | 0.870–5.530 |
| Xie et al., 2013 [22] | R | 308 | HCC | I–IV | Tissue | IHC | Score > 6 | 126/308 | OS | Reported | 4.823 | 3.257–6.893 |
| Ji et al., 2014 [23] | R | 60 | HCC | I–IV | Tissue | IHC | Score ≥ 3 | 41/60 | OS | Reported | 2.827 | 1.030–7.759 |
| Gao et al., 2014 [24] | R | 160 | HCC | N/A | Tissue | qRT-PCR | ROC curve | 72/160 | OS | Reported | 2.280 | 1.453–3.580 |
| Stein et al., 2009 [3] | C | 60 | CRC | I–III | Tissue | qRT-PCR | Median value | 30/60 | MFS | Estimated | 3.340 | 1.820–6.130 |
| Isella et al., 2013 [25] | R | 64 | CRC | N/A | Tissue | qRT-PCR | >−1.30 | 51/64 | RFS DFS |
Estimated Reported |
1.880 7.274 |
1.210–2.920 1.658–31.905 |
| Kawamura et al., 2012 [26] | R | 52 | CRC | II-III | Tissue | qRT-PCR | 0.261 | 18/52 | RFS | Estimated | 2.100 | 1.030–4.300 |
Study design is described as consecutive patients (C) or retrospective (R). Cancer subgroups include colorectal cancer (CRC), gastric cancer (GC), esophageal cancer (EC), and hepatocellular cancer (HCC). Clinical outcomes include overall survival (OS), metastasis-free survival (MFS), relapse-free survival (RFS), and disease-free survival (DFS). MACC1 measurement is categorized as quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC) group.